Venus Medtech (Hangzhou) Inc. (VMTHF)

Market Cap	66.43M -65.6%
Revenue (ttm)	37.56M -40.3%
Net Income	-68.34M
EPS	-0.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	222.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Open	0.4219
Previous Close	0.4219
Day's Range	0.4219 - 0.4219
52-Week Range	0.1963 - 0.5196
Beta	1.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2009
• Employees: 557
• Stock Exchange: OTCMKTS
• Ticker Symbol: VMTHF

Financial Performance

In 2025, Venus Medtech (Hangzhou)'s revenue was 306.79 million, a decrease of -34.84% compared to the previous year's 470.83 million. Losses were -407.69 million, -42.92% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 25, 2026

Data Sources Report a data error